Kalypsys is a clinical stage pharmaceutical company focused on the discovery and development of novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The company was founded on an innovative discovery platform to rapidly identify lead candidates against traditionally challenging molecular targets, based on technology developed at the Genomics Institute of the Novartis research Foundation (GNF) in La Jolla, California. The company has advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The lead molecule, KD1157, acts at a novel molecular target, presenting the opportunity for a first-in-class product in allergic rhinitis.


Allergic rhinitis is a highly prevalent disease worldwide, with significant negative impact on quality of life and productivity of sufferers. Despite the availability of steroid and H1 Receptor antagonist-based products, the symptoms of up to 24 million patients are underserved in the US alone. The novel mechanism of action of the Kalypsys lead molecule, designated KD1157, will offer these allergic rhinitis sufferers a safe and effective new treatment option. KD1157 has been formulated for nasal delivery using standard intranasal delivery methods. KD1157 Nasal Spray has demonstrated a strong safety profile in non-clinical studies and in a clinical trial of healthy volunteers, and is now being studied in volunteer patients in clinical proof of concept trials.